Biosimilar Uptake in Medicare Advantage vs Traditional Medicare

Steven Kozlowski; Andrew Kwist; Rowan McEvoy; Nirabh Koirala; Yoganand Chillarige; Jeffrey A Kelman; David J Graham

doi:10.1001/jamahealthforum.2023.4335

Biosimilar Uptake in Medicare Advantage vs Traditional Medicare

JAMA Health Forum. 2023 Dec 1;4(12):e234335. doi: 10.1001/jamahealthforum.2023.4335.

Authors

Steven Kozlowski¹, Andrew Kwist², Rowan McEvoy², Nirabh Koirala², Yoganand Chillarige², Jeffrey A Kelman³, David J Graham¹

Affiliations

¹ Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
² Acumen LLC, Burlingame, California.
³ Centers for Medicare & Medicaid Services, Washington, DC.

No abstract available

Plain language summary

This cross-sectional study uses Traditional Medicare and Medicare Advantage claims data to evaluate uptake of biosimilars relative to their reference products.

MeSH terms

Biological Transport
Biosimilar Pharmaceuticals*
Medicare Part C*
United States

Substances

Biosimilar Pharmaceuticals